Pliant Therapeutics News and Activities

Pliant Therapeutics is a company listed under the stock ticker PLRX (US).

View the org chart displaying its 26 main executives

Most searched biographies at Pliant Therapeutics

• Bernard Coulie, Chief Executive Officer and Director
• Suzanne Bruhn, Board Member
• Hoyoung Huh, Chairman of the Board

Popular executive movements at Pliant Therapeutics

• Hans Hull, Chief Business Officer, has left the company  (posted on November 27 2025).

Create your alert
to follow the executive moves at Pliant Therapeutics.

Pliant Therapeutics has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).

Popular M&A news in Pharmaceuticals

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
• Hims & Hers has acquired Eucalyptus (posted on June 2 2026).

Popular contacts in Pharmaceuticals

• Joaquin Duato - Chief Executive Officer and Chairman of the Board at Johnson & Johnson
• Richard Saynor - Chief Executive Officer at Sandoz
• Robert Ford - Chief Executive Officer and Chairman of the Board at Abbott

Learn more about the Pharmaceuticals industry

Press releases by Pliant Therapeutics

• Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting | Pliant Therapeutics, Inc.
• Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results | Pliant Therapeutics, Inc.
• Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference | Pliant Therapeutics, Inc.
• Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors | Pliant Therapeutics, Inc.
• Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting | Pliant Therapeutics, Inc.
• Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting | Pliant Therapeutics, Inc.
• Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results | Pliant Therapeutics, Inc.
• Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors | Pliant Therapeutics, Inc.
• Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference | Pliant Therapeutics, Inc.
• Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results | Pliant Therapeutics, Inc.
• View more press releases Close

Social media about Pliant Therapeutics

• Pliant Therapeutics on Wikipedia, Google News & Yahoo Finance
• Pliant Therapeutics on LinkedIn, X (Twitter) & YouTube